<DOC>
	<DOCNO>NCT00846586</DOCNO>
	<brief_summary>This study assess efficacy safety indacaterol ( 150 µg daily [ od ] ) combine tiotropium ( 18 µg od ) versus tiotropium ( 18 µg od ) treatment alone patient chronic obstructive pulmonary disease ( COPD )</brief_summary>
	<brief_title>Efficacy Safety Indacaterol Plus Tiotropium Versus Tiotropium Alone Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis chronic obstructive pulmonary disease ( COPD ) ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease [ GOLD ] Guidelines , 2007 ) : 1 . Smoking history least 10 packyears 2 . Postbronchodilator force expiratory volume 1 second ( FEV1 ) ≤ 65 % ≥ 30 % predict normal value 3 . Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Patients COPD exacerbation require systemic glucocorticosteroid treatment antibiotic and/or hospitalization 6 week prior screen runin period Patients respiratory tract infection within 6 week prior screen runin period Patients body mass index less 15 40 kg/m^2 Patients concomitant pulmonary disease Patients history asthma Patients diabetes Type I uncontrolled diabetes Type II Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
	<keyword>tiotropium</keyword>
	<keyword>bronchodilation</keyword>
</DOC>